预约演示
Chutes & Ladders—Apnimed, unafraid of solo commercial mission, brings on Nurtec ODT architect
2024-01-26
高管变更并购临床3期IPO
None
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.
Apnimed brings on Biohaven and Pfizer’s commercial migraine leader
Apnimed
Apnimedneed any moBiohavennce tPfizernimed is keepimigrainef its options open, look no further than the biotech’s latest hire. The company is bringing on Graham Goodrich as chief commercial officer, one of the key architects of Biohaven’s migraine medication Nurtec ODT. He was the senior vice president of brand marketing at the Connecticut biotech before Biohaven sold the franchise to Pfizer for $11.6 billion in 2022.
Goodrich stayed on after the sale, becoming senior vice president of the migraine market at Pfizer. The drug raked in $646 million for Pfizer through the first nine months of 2023, including $233 million in the third quarter.
Apnimed’s prize possession is an orApnimed to treat sleep apnea, upending a market that’s largely dominabiotechCPAP machines and devices. That med, AD109, is currently in the middle of its phase 3 program with data expected in tBiohaven hamigraine25 and an NDA expected shortly after, assuming the data are positive. In an interview with Fierbiotechech, GooBiohavenys he’s often gravitatePfizerrd working on treating large, common diseases with stagnant innovation.
Chief Business Officer Barry Wohl said as part of thsleep apneaerview that the company has mulled a number of different strategic routes, from an IPAD109potential business development. But Goodrich’s hire was meant to solidify that should Apnimed still be the sole owners of AD109 by the time of a potential approval, they’ll be ready to market it without issue.
“We wouldn't be bringing on someone of Graham's caliber and setting up our commercial organization if we didn't think that there was a reasonable chance that we will be marketing AD109 one day,” he said. Release
Eli LillyAD109
Lillyimes when executives “retire,” it’s code for “you’ll be seeing me at a new job soon.” That’s less likely to be the case for Johna Norton, who’s wrapping up a 34-year career at Eli Lilly. The executive vice president of global quality will officially leave at the end of July.
Eli Lillyis already underway for her replacement, but she’ll continue in a full capacity both as head of quality and as a member of the executive team until her departure date. Lilly CEO David Ricks lauded her tenure and commitment to top-tier manufacturing standards in the company’s press release.
“By ensuring our company, manufacturing sites, production lines, team members and collaborators share this commitment, she has had a profound and positive impact on patients and ourEli Lilly" he said.
Norton joined the company in 1990—more than five years before the authors of this column were born—as an analytical chemist before moving into quality control and quality assuraLillyShe led work on the manufacturing of Lilly’s first monoclonal antibodies and the quality checklist for the company’s first monoclonal production facility in Ireland. Release
Neumora brings on Cerevel’s commercial head fresh off AbbVie buy
NeumoraLilly
Now, the AbbVie connection is being revisited again, with Gosebruch making one of his biggest hires to date. The biotech is bringing on Kaya Pai-Panandiker as its chief commercial officer after she was head of commercial at Cerevel. Less than two months ago, AbbVie bought the neuroscience biotech for $8.7 billion. Before joining Cerevel, Pai-Panandiker was the general manager of neuroscience at Lundbeck, helping lead that therapeutic area’s commercial strategy.
> BenevolAbbViehas a new CEO in Joerg Moeller, M.D., Ph.D., who joins from LEO Pharma, where he led R&D since 2021. Before that, Moeller spent almost 20 years at Bayer, moving up from the head of strategic development of theCerevelvascular unit to chief of glAbbVie&D for the pharma giant. Fierce BiotechCerevelLundbeck
> Bayer has picked Nelson Ambrogio to head up the pharmamajor depressionlogy navacaprantmbrogio, who most recently served SVP and general manager of Bayer’s oncology business in the U.S., takes the spot of Gerd Krueger, who has led the radiology arm for eight years. Release
> BenevolentAIstor Third Rock Ventures is welcoming new venture partners, iLEO Pharmaormer Karuna CEO Steve Paul, M.D.; Courtney Wallace, former chief business ofBayer at Beam Therapeutics; and TESARO co-founder Mary Lynne Hedley, Ph.D. The investment firm has also promoted Jigar Raythatha from venture partner to partner and elevated Vyas Ramanan, Ph.D., from principal to venture partner. Fierce Biotech
> Biotech PharmaceuThird Rock VenturesLisa Olson, Ph.D., to helm the antibody-focused bioteKarunason most recently served as chief scientific officer for Magenta TherapeutBeam Therapeuticsious lTESAROhip positions at AbbVie and Abbott Laboratories before that. Release
> PDS Biotech is welcoming Vlad Bykoriz, M.D., Ph.D., aboard as chief medical officer. Bykoriz has more than two decades of industry experience, holding roles at Abbott and Pfizer. ReleaseEisai
> Enthera Pharmaceuticalshas chosen Seemi Khan, M.D., to serve as the company’s chief medical officer. Khan most recently served as CMO for Reata PharmaceMagenta Therapeuticsacquisition by Biogen. ReleaseAbbVieAbbott Laboratories
> Immorta Bio, Ph.D., is taking up the top spot at SIGA Technologies as CEO Phillip Gomez, Ph.D., retires. Nguyen joins from Xalud Therapeutics, an inflammatory disease-focused biotech where she served as CEO. Release
> Alkeus Pharmaceuticals has elected Sanjay Keswani, M.D., to lead the neurodegenerative biotech as president and CEO. Previously, the physiReata Pharmaceuticalsld leadership roles at HoffmBiogenRoche, Bristol-Myers Squibb and Annexon, among others. Release
> Apellis Pharmaceuticals has appointed Chief CommeSIGA Technologiesm Townsend to serve as the company’s chief operating offiXalud TherapeuticsXaludTownsend has serveinflammatory diseasence 2018 and, before that, held a variety of leadership roles at Biogen. Release
> DiaMedica Therapeutics has tapped neurologist Lorianne Masuoka, M.D., to serve as the company’s chief medical officer. Previously, Masuoka held the top medical spot at Epygenix TheraHoffman La Roche PBristol-Myers Squibbst PhAnnexonticals (acquired by Merck & Co.), and Nektar Therapeutics. Release
> Apellis Pharmaceuticalsene has chosen James Wentworth, Ph.D., to take up spot as chief business officer. Most recently, Wentworth served as AdaptimmuneApellisctor of business development and strategy. ReleaseBiogen
> DiaMedica Therapeuticsd Morten Bull to serve as SVP, general counsel and head of people & business services. The lawyer worked with the pharma last year on a consultancEpygenix TherapeuticslyMarinus PharmaceuticalsreCubist Pharmaceuticalsf IP and R&D lMerck & Co. PharmaNektar Therapeutics
> Former Bayer HealTransgened Sanofi CEO Olivier Brandicourt, M.D., has joined BeiGene’s board of directors. Since retiring from the French phAdaptimmune9, Brandicourt has picked up director roles at Alnylam Pharmaceuticals, BenevolentAI, Dewpoint Therapeutics and AvenCell Therapeutics, and is also a senior advisor at Blackstone Life Sciences. Release
> NMD Pharmaciences selected Samuel Collins, Ph.D., to be its chief medical officer. Prior to joining the San Diego biotech, Collins’ two-decade career included stops at Therachon, Pfizer and, most recently, Edgewise Therapeutics, where he was VP of clinical devLEO PharmaRelease
> Nicola Bayer HealthCareD., iSanofiax’s new chief medical officer, taking the BeiGenerom Paul Willems, M.D. Groth joins the French vaccine maker after spending the better part of the last decade headAlnylam Pharmaceuticalsn BenevolentAIagDewpoint TherapeuticsAvenCell TherapeuticsBlackstone Life Sciences
> Actio Biosciencesuticals has found a new chief medical officer in one of its board members: Diana Hausman, M.D., who previously held CMO roles at Link ImmunotherapeuticTherachonThPfizertics, Zymeworks and OEdgewise Therapeuticswho has relinquished her spot on the board, is replacing Carrie Brownstein, M.D., who is stepping down from the CMO post for personal reasons. Meanwhile, Kyle Rasbach, Ph.D., Pharm.D., formerly of Eventide Asset Management, was tapped as Zentalis’ chief business officer. Release
> Following a round of layoffs aOsivaxipeline pare-down, Kronos Bio is now trimming its C-suite: The positions of Chief Medical Officer Jorge DiMartino, M.D., Chief Scientific Officer Christopher Dinsmore, Ph.D., and Chief Operating Officer and GenGSKl Counsel Barbara Kosacz have all been eliminated, making way for a “streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating needs.” Fierce Biotech
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。